Lipidomic characterization and localization of phospholipids in the human lung

Journal of Lipid Research

Volumn 58, Issue 5, 2017, Pages 926-933

  Zemski Berry, Karin A ^a   Murphy, Robert C ^a   Kosmider, Beata ^b   Mason, Robert J ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

Alveolar macrophages; Alveolar type II cells; Bronchial epithelial cells

Indexed keywords

PHOSPHOLIPID;

ARTICLE; BRONCHIAL EPITHELIAL CELL; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPIDOMICS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS MACROPHAGE; MASS SPECTROMETRY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION IMAGING MASS SPECTROMETRY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UNIVARIANT STATISTICAL ANALYSIS; BIOLOGY; CHEMISTRY; LIQUID CHROMATOGRAPHY; LUNG; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, LIQUID; COMPUTATIONAL BIOLOGY; HUMANS; LUNG; PHOSPHOLIPIDS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 85018876570     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M074955     Document Type: Article

References (52)

1. Samuelsson, B., S. E. Dahlén, J. A. Lindgren, C. A. Rouzer, and C. N. Serhan. 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237: 1171-1176.
2. Lewis, R. A., K. F. Austen, and R. J. Soberman. 1990. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323: 645-655.
3. Riccioni, G., T. Bucciarelli, B. Mancini, C. Di Ilio, and N. D'Orazio. 2007. Antileukotriene drugs: clinical application, effectiveness and safety. Curr. Med. Chem. 14: 1966-1977.
4. Bozyk, P. D., and B. B. Moore. 2011. Prostaglandin E2 and the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 45: 445-452.
5. Drakatos, P., D. Lykouras, F. Sampsonas, K. Karkoulias, and K. Spiropoulos. 2009. Targeting leukotrienes for the treatment of COPD? Inflamm. Allergy Drug Targets. 8: 297-306.
6. Zaslona, Z., and M. Peters-Golden. 2015. Prostanoids in asthma and COPD: actions, dysregulation, and therapeutic opportunities. Chest. 148: 1300-1306.
7. Konstan, M. W., G. Döring, S. L. Heltshe, L. C. Lands, K. A. Hilliard, P. Koker, S. Bhattacharya, A. Staab, and A. Hamilton; Investigators and Coordinators of BI Trial 543.45. 2014. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J. Cyst. Fibros. 13: 148-155.
8. Veldhuizen, R., K. Nag, S. Orgeig, and F. Possmayer. 1998. The role of lipids in pulmonary surfactant. Biochim. Biophys. Acta. 1408: 90-108.
9. Numata, M., H. W. Chu, A. Dakhama, and D. R. Voelker. 2010. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc. Natl. Acad. Sci. USA. 107: 320-325.
10. Wright, S. M., P. M. Hockey, G. Enhorning, P. Strong, K. B. Reid, S. T. Holgate, R. Djukanovic, and A. D. Postle. 2000. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J. Appl. Physiol. 89: 1283-1292.
11. Mander, A., S. Langton-Hewer, W. Bernhard, J. O. Warner, and A. D. Postle. 2002. Altered phospholipid composition and aggregate structure of lung surfactant is associated with impaired lung function in young children with respiratory infections. Am. J. Respir. Cell Mol. Biol. 27: 714-721.
12. Tibby, S. M., M. Hatherill, S. M. Wright, P. Wilson, A. D. Postle, and I. A. Murdoch. 2000. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 162: 1251-1256.
13. Balhara, J., and A. S. Gounni. 2012. The alveolar macrophages in asthma: a double-edged sword. Mucosal Immunol. 5: 605-609.
14. Zhao, C. Z., X. C. Fang, D. Wang, F. D. Tang, and X. D. Wang. 2010. Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease. Respir. Med. 104: 1391-1395.
15. Volsko, T. A. 2013. Airway clearance therapy: finding the evidence. Respir. Care. 58: 1669-1678.
16. Grainge, C. L., and D. E. Davies. 2013. Epithelial injury and repair in airways diseases. Chest. 144: 1906-1912.
17. Hiemstra, P. S., P. B. McCray, and R. Bals. 2015. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur. Respir. J. 45: 1150-1162.
18. Fehrenbach, H. 2001. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir. Res. 2: 33-46.
19. Chuquimia, O. D., D. H. Petursdottir, N. Periolo, and C. Fernández. 2013. Alveolar epithelial cells are critical in protection of the respiratory tract by secretion of factors able to modulate the activity of pulmonary macrophages and directly control bacterial growth. Infect. Immun. 81: 381-389.
20. Postle, A. D., L. W. Gonzales, W. Bernhard, G. T. Clark, M. H. Godinez, R. I. Godinez, and P. L. Ballard. 2006. Lipidomics of cellular and secreted phospholipids from differentiated human fetal type II alveolar epithelial cells. J. Lipid Res. 47: 1322-1331.
21. Zehethofer, N., S. Bermbach, S. Hagner, H. Garn, J. Müller, T. Goldmann, B. Lindner, D. Schwudke, and P. König. 2015. Lipid analysis of airway epithelial cells for studying respiratory diseases. Chromatographia. 78: 403-413.
22. Wang, J., K. Edeen, R. Manzer, Y. Chang, S. Wang, X. Chen, C. J. Funk, G. P. Cosgrove, X. Fang, and R. J. Mason. 2007. Differentiated human alveolar epithelial cells and reversibility of their phenotype in vitro. Am. J. Respir. Cell Mol. Biol. 36: 661-668.
23. Wang, J., M. P. Nikrad, E. A. Travanty, B. Zhou, T. Phang, B. Gao, T. Alford, Y. Ito, P. Nahreini, K. Hartshorn, et al. 2012. Innate immune response of human alveolar macrophages during influenza A infection. PLoS One. 7: e29879.
24. Ito, Y., K. Correll, J. A. Schiel, J. H. Finigan, R. Prekeris, and R. J. Mason. 2014. Lung fibroblasts accelerate wound closure in human alveolar epithelial cells through hepatocyte growth factor/c-Met signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 307: L94-L105.
25. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
26. Han, X., and R. W. Gross. 2005. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 24: 367-412.
27. Pulfer, M., and R. C. Murphy. 2003. Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev. 22: 332-364.
28. Berry, K. A., B. Li, S. D. Reynolds, R. M. Barkley, M. A. Gijón, J. A. Hankin, P. M. Henson, and R. C. Murphy. 2011. MALDI imaging MS of phospholipids in the mouse lung. J. Lipid Res. 52: 1551-1560.
29. Hankin, J. A., R. M. Barkley, and R. C. Murphy. 2007. Sublimation as a method of matrix application for mass spectrometric imaging. J. Am. Soc. Mass Spectrom. 18: 1646-1652.
30. Hsu, F. F., and J. Turk. 2000. Characterization of phosphatidylinositol, phosphatidylinositol-4-phosphate, and phosphatidylinositol-4,5-bisphosphate by electrospray ionization tandem mass spectrometry: a mechanistic study. J. Am. Soc. Mass Spectrom. 11: 986-999.
31. Kennedy, E. P., and S. B. Weiss. 1956. The function of cytidine coenzymes in the biosynthesis of phospholipides. J. Biol. Chem. 222: 193-214.
32. Lands, W. E. 1960. Metabolism of glycerolipids. 2. The enzymatic acylation of lysolecithin. J. Biol. Chem. 235: 2233-2237.
33. Chang, C. C. Y., J. Sun, and T-Y. Chang. 2011. Membrane-bound O-acyltransferases (MBOATs). Front. Biol. 6: 177-182.
34. Gijón, M. A., W. R. Riekhof, S. Zarini, R. C. Murphy, and D. R. Voelker. 2008. Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. J. Biol. Chem. 283: 30235-30245.
35. Chen, X., B. A. Hyatt, M. L. Mucenski, R. J. Mason, and J. M. Shannon. 2006. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc. Natl. Acad. Sci. USA. 103: 11724-11729.
36. Ghosh, M., D. E. Tucker, S. A. Burchett, and C. C. Leslie. 2006. Properties of the group IV phospholipase A2 family. Prog. Lipid Res. 45: 487-510.
37. Chu, H. W., S. Balzar, J. Y. Westcott, J. B. Trudeau, Y. Sun, D. J. Conrad, and S. E. Wenzel. 2002. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin. Exp. Allergy. 32: 1558-1565.
38. Shannon, V. R., P. Chanez, J. Bousquet, and M. J. Holtzman. 1993. Histochemical evidence for induction of arachidonate 15-lipoxygenase in airway disease. Am. Rev. Respir. Dis. 147: 1024-1028.
39. Profita, M., A. Sala, L. Riccobono, A. Paternò, A. Mirabella, A. Bonanno, D. Guerrera, E. Pace, G. Bonsignore, J. Bousquet, et al. 2000. 15-Lipoxygenase expression and 15(S)-hydroxyeicoisatetraenoic acid release and reincorporation in induced sputum of asthmatic subjects. J. Allergy Clin. Immunol. 105: 711-716.
40. Zhao, J., V. B. O'Donnell, S. Balzar, C. M. St Croix, J. B. Trudeau, and S. E. Wenzel. 2011. 15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells. Proc. Natl. Acad. Sci. USA. 108: 14246-14251.
41. Demoly, P., D. Jaffuel, N. Lequeux, B. Weksler, C. Créminon, F. B. Michel, P. Godard, and J. Bousquet. 1997. Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics. Am. J. Respir. Crit. Care Med. 155: 670-675.
42. Claar, D., T. V. Hartert, and R. S. Peebles. 2015. The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev. Respir. Med. 9: 55-72.
43. Liu, M. C., E. R. Bleecker, L. M. Lichtenstein, A. Kagey-Sobotka, Y. Niv, T. L. McLemore, S. Permutt, D. Proud, and W. C. Hubbard. 1990. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am. Rev. Respir. Dis. 142: 126-132.
44. Sousa, A. r., R. Pfister, P. E. Christie, S. J. Lane, S. M. Nasser, M. Schmitz-Schumann, and T. H. Lee. 1997. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax. 52: 940-945.
45. Montuschi, P. 2010. Role of leukotrienes and leukotriene modifiers in asthma. Pharmaceuticals (Basel). 3: 1792-1811.
46. Jame, A. J., P. M. Lackie, A. M. Cazaly, I. Sayers, J. F. Penrose, S. T. Holgate, and A. P. Sampson. 2007. Human bronchial epithelial cells express an active and inducible biosynthetic pathway for leukotrienes B4 and C4. Clin. Exp. Allergy. 37: 880-892.
47. Peters-Golden, M. 1998. Cell biology of the 5-lipoxygenase pathway. Am. J. Respir. Crit. Care Med. 157: S227-S231.
48. Lambrecht, B. N. 2006. Alveolar macrophage in the driver's seat. Immunity. 24: 366-368.
49. Zemski Berry, K. A., and R. C. Murphy. 2004. Electrospray ionization tandem mass spectrometry of glycerophosphoethanolamine plasmalogen phospholipids. J. Am. Soc. Mass Spectrom. 15: 1499-1508.
50. Engelmann, B. 2004. Plasmalogens: targets for oxidants and major lipophilic antioxidants. Biochem. Soc. Trans. 32: 147-150.
51. Bernhard, W., J. Y. Wang, T. Tschernig, B. Tümmler, H. J. Hedrich, and H. von der Hardt. 1997. Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in cftrm1HGU/m1HGU mice. Thorax. 52: 723-730.
52. Postle, A. D., E. L. Heeley, and D. C. Wilton. 2001. A comparison of the molecular species compositions of mammalian lung surfactant phospholipids. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 129: 65-73.